Sanofi (NASDAQ:SNY) Stock Rating Upgraded by StockNews.com

StockNews.com upgraded shares of Sanofi (NASDAQ:SNY) from a buy rating to a strong-buy rating in a research report sent to investors on Thursday morning.

Separately, Argus boosted their target price on shares of Sanofi from $55.00 to $60.00 and gave the stock a buy rating in a report on Friday, July 26th. Three equities research analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of Moderate Buy and an average price target of $57.50.

Sanofi Stock Up 2.7 %

Shares of SNY opened at $53.05 on Thursday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00. Sanofi has a 52 week low of $42.63 and a 52 week high of $55.72. The stock has a market capitalization of $134.36 billion, a price-to-earnings ratio of 26.66, a PEG ratio of 1.50 and a beta of 0.59. The stock has a fifty day moving average of $49.51 and a 200-day moving average of $48.67.

Sanofi (NASDAQ:SNY) last issued its earnings results on Thursday, July 25th. The company reported $0.93 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.88 by $0.05. The business had revenue of $10.75 billion during the quarter, compared to analysts’ expectations of $16.86 billion. Sanofi had a return on equity of 26.29% and a net margin of 9.60%. The business’s revenue for the quarter was up 7.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.95 EPS. As a group, sell-side analysts anticipate that Sanofi will post 4.16 earnings per share for the current fiscal year.

Institutional Trading of Sanofi

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Cardinal Capital Management boosted its stake in shares of Sanofi by 0.3% in the 4th quarter. Cardinal Capital Management now owns 58,854 shares of the company’s stock valued at $2,927,000 after purchasing an additional 201 shares during the last quarter. TCTC Holdings LLC lifted its holdings in Sanofi by 28.0% in the first quarter. TCTC Holdings LLC now owns 960 shares of the company’s stock valued at $47,000 after buying an additional 210 shares during the period. Daiwa Securities Group Inc. grew its holdings in Sanofi by 3.4% during the 4th quarter. Daiwa Securities Group Inc. now owns 6,541 shares of the company’s stock worth $325,000 after acquiring an additional 216 shares during the period. HB Wealth Management LLC raised its position in shares of Sanofi by 3.7% in the 2nd quarter. HB Wealth Management LLC now owns 6,166 shares of the company’s stock worth $299,000 after acquiring an additional 221 shares in the last quarter. Finally, Wynn Capital LLC lifted its stake in shares of Sanofi by 4.5% in the 1st quarter. Wynn Capital LLC now owns 5,266 shares of the company’s stock valued at $256,000 after purchasing an additional 226 shares during the period. Institutional investors and hedge funds own 10.04% of the company’s stock.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.